UNSPSC 51351630: Estrone benzoate

This classification denotes an estrogen with the molecular formula C25H26O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O636LYL5W8, chemically known as estra-1,3,5(10)-trien-17-one, 3-(benzoyloxy)-, but more generally known as estrone benzoate, which bears US NIH Compound Identifier 16963. European Medicines Agency schedules estrone benzoate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07251MIG. Most nations, for tariff purposes, schedule estrone benzoate under HS 29372300.

SMILES: C[C@]12CC[C@@H]3C4CCC(CC4CC[C@H]3[C@@H]1CCC2=O)OC(=O)C5CCCCC5.

UNSPSC 51351630 Estrone benzoate is a Commodity code representing pharmaceutical ingredients and active pharmaceutical substances sourced by state and local healthcare systems. Recent state and local procurement under this code focuses on establishing master supply agreements for generic multi-source pharmaceuticals and over-the-counter products distributed through cooperative purchasing vehicles and authorized wholesalers. Estrone benzoate and related hormone-based pharmaceuticals fall within these broader generic pharmaceutical procurement initiatives, which require vendors to maintain cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, and contractual relationships with established pharmaceutical wholesalers. Issuing bodies soliciting under this code include state health departments and multistate cooperative purchasing alliances administering contracts on behalf of participating state and local government facilities, hospitals, clinics, and other healthcare entities.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP (S1070000015802) on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. Vendors must supply products through authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), maintain specified insurance coverage including $5 million commercial general liability per occurrence, and submit pricing in designated formats with National Drug Codes and product specifications. The resulting contracts, effective July 1, 2026, carry a two-year initial term with optional extensions, and pricing evaluation is weighted 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and the remainder on EDI capability, administrative fee compliance, and administrative data format compliance. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs, with no specific award values disclosed in available materials.